MMP-2200

**MMP-2200** is a glycosylated enkephalin analog (glycopeptide) engineered for enhanced blood-brain barrier penetration and increased in vivo stability. It has approximately equal nanomolar affinity and efficacy for the δ opioid receptor and μ opioid receptor. The compound is a mixed δ/μ opioid receptor agonist that demonstrates strong antinociceptive (pain-relieving) efficacy in preclinical models, with systemic administration (i.p., s.c., i.v.) leading to substantial central nervous system (CNS) effects. MMP-2200 exhibits robust behavioral effects in models of pain and striatal dopamine depletion and provides a favorable side-effect profile compared to morphine, including reduced propensity for locomotor stimulation, tolerance, and dependence. Its mechanism and glycosylated structure result in improved CNS delivery compared to standard enkephalin peptides. Preclinical research suggests MMP-2200 may be further developed for applications like pain relief and potentially for neurological disorders with dopaminergic deficits[1][2][3].